Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Johann swims his way to Olympics
2016-05-18


Johann van Heerden from the University of the Free State has qualified for the Paralympic Games in the swimming pool, and is now waiting to hear if he will be included in the South African team. Photo: Nadya van Heerden.

In the past couple of months, Johann van Heerden has been swimming his way to the Paralympic Games, and is still preparing as if he will be going to Rio de Janeiro.

The Kovsie swimmer, who will know whether he has been included in the Paralympic team in July 2016, feels his training is progressing well. The Olympics will be held in Brazil from 7 to 18 September 2016. If all goes well, this could be the first of several Olympics for the 20-year-old second-year Education student from the University of the Free State (UFS).

Dream year for Education student

Van Heerden (cerebral palsy), whose hero is the former Paralympic superstar Natalie du Toit, has had huge successes in the run-up to the 2016 Olympics. Among others, he was named the best senior swimmer at the Nedbank National Championships for the Physically Disabled in Bloemfontein in March 2016. At the South African Senior Championships in Durban in April 2016, he qualified for the Olympics in the 100 m breast-stroke with an A-qualifying time, and in the 50 m and 100 m freestyle with B-qualifying times.

Only three male swimmers to Olympics

However, he has to wait until the announcement of the South African Paralympic team, since only three male and three female swimmers will be selected. He will not be competing in another major event before the Olympics. “My short-term goal is to compete in this year’s Games, and, in the long term, I would like to reach even greater heights at the 2020 Games,” he said. Du Toit is an inspiration to him because “she was hard-working, and she had a lot of drive”.

Other students from CUADS also excel

At the above-mentioned National Championships, Van Heerden won a total of five gold medals (200 m medley, 100 m breaststroke, 50 m freestyle, 50 m breaststroke, and 200 m breaststroke) and one silver medal (100 m freestyle). Other students from the Center for Universal Access and Disability Support at the UFS also excelled.

Dineo Mokhosoa (cerebral palsy) won three gold medals (long jump, shot-put, and discus), while the athlete Louzanne Coetzee (blind) shattered the world record in the 5 000 m, as well as the Africa record in the 1 500 m. Juanré Jenkinson (cerebral palsy) won two silver medals (discus and shot-put) while Danie Breitenbach (blind) won two gold medals (800 m and 1500 m).

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept